We are committed to expanding our portfolio and our pipeline in therapeutic areas that can leverage our unique expertise and growing our global footprint.
As a leader in sleep medicine and with a growing hematology/oncology portfolio, we develop meaningful medicines and bring them to people with unaddressed needs around the world. We seek solutions for rare or complex diseases, and ensure those solutions are available for the often-overlooked patients who need them.
Jazz is committed to addressing unmet needs in sleep medicine by delivering meaningful treatment options to patients – in particular for patients with cataplexy or excessive daytime sleepiness in narcolepsy, and excessive daytime sleepiness in obstructive sleep apnea (OSA).
Jazz is the industry leader in sleep medicine innovation with a robust R&D program focused on enhancing our current therapies and developing new treatments for patients with chronic and often debilitating sleep disorders. Learn more about our R&D.
Jazz has expanded its hematology/oncology portfolio and remains committed to hematology/oncology – with a focus in the areas of acute leukemias, both lymphocytic and myeloid (ALL and AML) and for patients who develop an ultra-rare complication of hematopoietic stem cell transplantation (HSCT), known as veno-occlusive disease (VOD).
We are committed to innovation in hematology/oncology to address patients’ unmet needs for new therapeutic options, and our R&D efforts also focus on expanding the science behind our medicines. Learn more about our R&D.
Learn more about Our Medicines.